Canton Strategic Holdings (CNTN) Return on Capital Employed (2022 - 2026)
Canton Strategic Holdings (CNTN) posted Return on Capital Employed of 9.88% for Q1 2026, down 27.86% on a QoQ basis from 7.73% in Q4 2025, and up 583685.0% year-over-year from N/an in Q1 2025.
Canton Strategic Holdings (CNTN) Return on Capital Employed (2022 - 2026) Analysis & Trends
Canton Strategic Holdings' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 9.88% for Q1 2026.
- Quarterly Return on Capital Employed rose 583685.0% year-over-year to 9.88% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.88% (up 583685.0% YoY) and the FY2025 annual result came in at 7.79%, up 24424.0% from the prior year.
- Return on Capital Employed was 9.88% for Q1 2026 at Canton Strategic Holdings, down from 7.73% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 18004.79% in Q2 2025 and bottomed at 5846.74% in Q1 2025.
- A 5-year average of 557.17% and a median of 129.79% in 2024 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 1813458 bps in 2025, while the deepest fall reached 573424 bps in 2025.
- Canton Strategic Holdings' Return on Capital Employed stood at 110.85% in 2022, then sank by 63 bps to 180.39% in 2023, then slumped by 232 bps to 598.32% in 2024, then soared by 99 bps to 7.73% in 2025, then decreased by 28 bps to 9.88% in 2026.
- Business Quant data shows CNTN's Return on Capital Employed at 9.88% in Q1 2026, 7.73% in Q4 2025, and 288.64% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Canton Strategic Holdings | 427.87 Mn | 427.87 Mn | - | -9.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.88% |
| Dec 31, 2025 | -7.73% |
| Sep 30, 2025 | -288.64% |
| Jun 30, 2025 | 18,004.79% |
| Mar 31, 2025 | -5,846.74% |
| Dec 31, 2024 | -598.32% |
| Sep 30, 2024 | -245.93% |
| Jun 30, 2024 | -129.79% |
| Mar 31, 2024 | -112.49% |
| Dec 31, 2023 | -180.39% |
| Sep 30, 2023 | -351.39% |
| Jun 30, 2023 | -286.64% |
| Mar 31, 2023 | -197.06% |
| Dec 31, 2022 | -110.85% |
| Sep 30, 2022 | -63.39% |
| Jun 30, 2022 | -36.45% |
| Mar 31, 2022 | -67.15% |